Newer pacing method matched standard cardiac resynchronization therapy with respect to clinical outcomes in the first ...
Bayer argued that key claims in J&J’s marketing materials are rooted in flawed data, which could mislead doctors and patients ...
Good afternoon, and welcome to Bausch Health's First Quarter 2026 Earnings Conference Call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas ...
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of ...
Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, ...
The Challenge of Safe Recovery in Elderly Thoracic PatientsAs the elderly population grows, so does the prevalence of lung ...
Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...
C-Suite executives are being warned that a previously undocumented Microsoft attack platform, codename Venom, can neutralize ...
Most executives optimize how they think but ignore where they think. These three hidden biological inputs shape executive ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million 1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results